K&L Gates LLP
Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.
Targeted Molecular Diagnostics
G G G G C C G C G
G01N G01N G01N G01N C12Q C12Q G01N C12Q G01N
additional additional additional additional inventional additional inventional additional additional
Jason Sarah S.
Hill Bacus